載入...
Information provision for antibacterial dosing in the obese patient: a sizeable absence?
BACKGROUND: Obesity is on course to overtake being underweight as a global disease burden. Obesity alters antibacterial pharmacokinetics (PK) and pharmacodynamics (PD). Historically, drug PK/PD parameters have not been studied in obese populations. This means dose recommendations risk being sub-ther...
Na minha lista:
| 發表在: | J Antimicrob Chemother |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Oxford University Press
2016
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5890658/ https://ncbi.nlm.nih.gov/pubmed/27538956 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkw324 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|